Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.

Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

BeOne aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 -- $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their ...

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...